{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:51:03Z","timestamp":1786945863043,"version":"build-2736575974"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.drudis.2013.07.021","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T12:47:59Z","timestamp":1375793279000},"page":"51-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations"],"prefix":"10.1016","volume":"19","author":[{"given":"Han Kiat","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Hui Ling","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse Siang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Tin","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2013.07.021_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drudis.2013.07.021_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2013.07.021_bib0015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(91)90512-W","article-title":"Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor","volume":"64","author":"Yayon","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2013.07.021_bib0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0025","first-page":"211","article-title":"Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer","volume":"21","author":"Sato","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.drudis.2013.07.021_bib0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/00365599.2011.552436","article-title":"Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma","volume":"45","author":"Tsimafeyeu","year":"2011","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jdermsci.2008.07.012","article-title":"Overexpression of the fibroblast growth factor receptor 2-IIIc in Kaposi's sarcoma","volume":"53","author":"Cottoni","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.drudis.2013.07.021_bib0040","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1158\/1535-7163.MCT-12-0243","article-title":"Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells","volume":"11","author":"Matsuda","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0045","first-page":"307","article-title":"Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer","volume":"28","author":"Matsunobu","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth","volume":"11","author":"Gomez-Roman","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","article-title":"Fibroblast growth factor signaling in tumorigenesis","volume":"16","author":"Grose","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.drudis.2013.07.021_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000308303","article-title":"Overexpression of KLF13 and FGFR3 in oral cancer cells","volume":"128","author":"Henson","year":"2010","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2008.08.015","article-title":"Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention","volume":"50","author":"Ho","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0070","first-page":"133","article-title":"Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma","volume":"38","author":"Motoda","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0075","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1002\/cncr.26207","article-title":"Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression","volume":"117","author":"Ye","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2013.07.021_bib0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molmed.2011.01.012","article-title":"Targeting mutant fibroblast growth factor receptors in cancer","volume":"17","author":"Greulich","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2013.07.021_bib0085","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2013.07.021_bib0090","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2013.07.021_bib0095","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/onc.2009.432","article-title":"The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells","volume":"29","author":"Roidl","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2013.07.021_bib0100","first-page":"840","article-title":"Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele","volume":"62","author":"Bange","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1593\/neo.08450","article-title":"Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression","volume":"10","author":"Wang","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.drudis.2013.07.021_bib0110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/ng1122","article-title":"Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome","volume":"33","author":"Dode","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2013.07.021_bib0115","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0022-3565(24)36726-6","article-title":"Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor","volume":"281","author":"Dahring","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-3565(24)37619-0","article-title":"In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase","volume":"286","author":"Panek","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0125","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1093\/emboj\/17.20.5896","article-title":"Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain","volume":"17","author":"Mohammadi","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2013.07.021_bib0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/0929867311320100001","article-title":"Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing","volume":"20","author":"Ho","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0135","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/jm000161d","article-title":"3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase","volume":"43","author":"Thompson","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0140","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/jm0500931","volume":"48","author":"Thompson","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1126\/science.276.5314.955","article-title":"Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors","volume":"276","author":"Mohammadi","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2013.07.021_bib0150","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1021\/jm9904295","article-title":"Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases","volume":"42","author":"Sun","year":"1999","journal-title":"J .Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0155","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0160","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0165","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2013.07.021_bib0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/187152012800228652","article-title":"Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds","volume":"12","author":"Yu-Jing","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0175","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1021\/jm990345w","article-title":"Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors","volume":"42","author":"Hennequin","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0180","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-10-2700","article-title":"E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models","volume":"71","author":"Bello","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0185","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm800790t","article-title":"Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors","volume":"52","author":"Renhowe","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0190","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1182\/blood-2007-02-074286","article-title":"Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome","volume":"110","author":"Chase","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2013.07.021_bib0195","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0200","first-page":"3801","article-title":"Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer","volume":"27","author":"Hackett","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0205","first-page":"607","article-title":"Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors","volume":"10","author":"Fry","year":"1995","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.drudis.2013.07.021_bib0210","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2013.07.021_bib0215","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2012.07.001","article-title":"Anticancer molecules targeting fibroblast growth factor receptors","volume":"33","author":"Liang","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drudis.2013.07.021_bib0220","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1016\/j.bmcl.2006.03.069","article-title":"Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases","volume":"16","author":"McBride","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2013.07.021_bib0225","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0230","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1535-7163.MCT-11-0426","article-title":"Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models","volume":"10","author":"Squires","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0235","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/jm0501275","article-title":"Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors","volume":"48","author":"Borzilleri","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0240","first-page":"4477","article-title":"Brivanib, a novel dual VEGF-R2\/bFGF-R inhibitor","volume":"30","author":"Dempke","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0245","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1021\/jm200258t","article-title":"Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity","volume":"54","author":"Chen","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0250","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0255","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0260","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drudis.2013.07.021_bib0265","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.bmc.2005.05.012","article-title":"RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation","volume":"13","author":"McDermott","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0270","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/jm901386e","article-title":"Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening","volume":"53","author":"Ravindranathan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2010.02.007","article-title":"A structure-guided approach to creating covalent FGFR inhibitors","volume":"17","author":"Zhou","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ccr.2013.02.019","article-title":"Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties","volume":"23","author":"Bono","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2013.07.021_bib0285","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2013.02.018","article-title":"Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling","volume":"23","author":"Herbert","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2013.07.021_bib0290","unstructured":"U.S. National Institutes of Health, available at: http:\/\/www.clinicaltrials.gov\/(accessed July 2013)."},{"key":"10.1016\/j.drudis.2013.07.021_bib0295","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0300","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2217\/fon.11.116","article-title":"Pazopanib: a promising new agent in the treatment of soft tissue sarcomas","volume":"7","author":"Kasper","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0305","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14740338.2012.712108","article-title":"Safety and tolerability of pazopanib in the treatment of renal cell carcinoma","volume":"11","author":"Zivi","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drudis.2013.07.021_bib0310","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2013.07.021_bib0315","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Meulenbeld","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2013.07.021_bib0325","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0330","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-09-2541","article-title":"MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0335","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.2174\/092986707781368504","article-title":"Monoclonal antibody gold rush","volume":"14","author":"Maggon","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0340","doi-asserted-by":"crossref","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2013.07.021_bib0345","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1158\/1078-0432.CCR-05-0282","article-title":"Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation","volume":"11","author":"Martinez-Torrecuadrada","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0350","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","article-title":"Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice","volume":"119","author":"Qing","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2013.07.021_bib0355","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/1535-7163.MCT-10-0417","article-title":"Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1","volume":"9","author":"Ronca","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2013.07.021_bib0360","doi-asserted-by":"crossref","first-page":"E964","DOI":"10.1152\/ajpendo.00089.2006","article-title":"Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys","volume":"292","author":"Sun","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2013.07.021_bib0365","doi-asserted-by":"crossref","first-page":"e57322","DOI":"10.1371\/journal.pone.0057322","article-title":"Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2013.07.021_bib0370","doi-asserted-by":"crossref","first-page":"45926","DOI":"10.1074\/jbc.M404824200","article-title":"A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome","volume":"279","author":"Tanimoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0375","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1091\/mbc.9.10.2785","article-title":"Fibroblast growth factor (FGF) soluble receptor 1 acts as a natural inhibitor of FGF2 neurotrophic activity during retinal degeneration","volume":"9","author":"Guillonneau","year":"1998","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.drudis.2013.07.021_bib0380","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrd3448","article-title":"Deal watch: HGS and FivePrime in FGF \u2018ligand trap\u2019 deal","volume":"10","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2013.07.021_bib0385","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"White","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2013.07.021_bib0390","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","article-title":"Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo","volume":"143","author":"Shimada","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2013.07.021_bib0395","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2013.07.021_bib0400","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2013.07.021_bib0405","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/onc.2009.203","article-title":"Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling","volume":"28","author":"Palamakumbura","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2013.07.021_bib0410","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00403-002-0333-z","article-title":"Immunolocalization of fibroblast growth factor receptors in normal and wounded human skin","volume":"294","author":"Takenaka","year":"2002","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0415","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.2003.83.3.835","article-title":"Regulation of wound healing by growth factors and cytokines","volume":"83","author":"Werner","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.drudis.2013.07.021_bib0420","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0425","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0430","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","article-title":"Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members","volume":"27","author":"Goetz","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0435","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0440","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2013.07.021_bib0445","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bone.2006.12.062","article-title":"FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23","volume":"40","author":"Fukumoto","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.drudis.2013.07.021_bib0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s003359900703","article-title":"Genomic structure and complete sequence of the human FGFR4 gene","volume":"9","author":"Kostrzewa","year":"1998","journal-title":"Mammalian Genome"},{"key":"10.1016\/j.drudis.2013.07.021_bib0455","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2013.07.021_bib0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J. Support. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0465","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drudis.2013.07.021_bib0470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2013.07.021_bib0475","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbrc.2011.03.002","article-title":"Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure","volume":"407","author":"Azuma","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2013.07.021_bib0480","doi-asserted-by":"crossref","first-page":"e14117","DOI":"10.1371\/journal.pone.0014117","article-title":"Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression","volume":"5","author":"Ware","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2013.07.021_bib0485","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1517\/13543780903183528","article-title":"Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma","volume":"18","author":"Dietrich","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2013.07.021_bib0490","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/1078-0432.CCR-09-1445","article-title":"A Phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors","volume":"15","author":"Cohen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0495","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0500","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.tps149","article-title":"First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors","volume":"29","author":"Soria","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.03.015","article-title":"A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells","volume":"307","author":"Qiu","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drudis.2013.07.021_bib0510","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1200\/jco.2011.29.15_suppl.5503","article-title":"A Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)","volume":"29, abstr.","author":"Sherman","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0515","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","article-title":"Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)","volume":"46","author":"Le Cesne","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2013.07.021_bib0520","doi-asserted-by":"crossref","first-page":"14657","DOI":"10.1200\/jco.2008.26.15_suppl.14657","article-title":"First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors","volume":"26","author":"Camacho","year":"2008","journal-title":"J. Clin. Oncol. (Meeting Abstracts)"},{"key":"10.1016\/j.drudis.2013.07.021_bib0525","doi-asserted-by":"crossref","first-page":"20644","DOI":"10.1074\/jbc.M109.083626","article-title":"NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells","volume":"285","author":"Krejci","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.07.021_bib0530","doi-asserted-by":"crossref","first-page":"C469","DOI":"10.1152\/ajpcell.00452.2010","article-title":"NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats","volume":"301","author":"Lin","year":"2011","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0535","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-010-1320-2","article-title":"A Phase I\/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma","volume":"67","author":"Kanai","year":"2011","journal-title":"Cancer Chemother. Pharmol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0540","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2013.07.021_bib0545","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2013.07.021_bib0550","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1078-0432.1336.11.3","article-title":"Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth","volume":"11","author":"Ezzat","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0555","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-07-5229","article-title":"FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival","volume":"68","author":"Kunii","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2013.07.021_bib0560","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644613002596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644613002596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:16:32Z","timestamp":1761221792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644613002596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1359644613002596"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2013.07.021","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2013.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}